NEW

Clinical Trials with the PAP DEVICE Asklipios Model for Human Use.

 

An application for Investigation Testing Authorization has been submitted to Health Canada. The title of the study is “Single Blind, Placebo Controlled, Randomized, Three Arm Safety and Efficacy study of the PAP Asklipios Ion Magnetic Inductor device in the Treatment of Rheumatic Pain”.

 

Pending approval from Health Canada, the study should be conducted in one site in the city of Toronto, Ontario, Canada. The indication for treatment will be Rheumatic Pain.  The total number of patients to be enrolled will be 100. Once the study is approved, the conditions to participate will be posted as well as a phone number to request an appointment with the investigator.